We took this decision to suspend temporarily until the connection could be fully clarified
In the long human effort to contain dengue fever, Brazil's Health Ministry paused the Butantan Institute's vaccine campaign on June 9th after surveillance systems detected two deaths and three severe cases among more than half a million recipients — a rare but serious signal that demanded investigation before the program could continue. The suspension is precautionary, not conclusive, and reflects the tension inherent in mass immunization: the imperative to protect many must be weighed carefully against harm to the few. While the Takeda vaccine continues for younger age groups, the episode reminds us that public health vigilance is not a failure of science, but its most honest expression.
- Two deaths and three cases of severe illness among 501,000 vaccinated people triggered an immediate halt to Brazil's Butantan dengue vaccine campaign on June 9th.
- Of more than 3,700 people who reported dengue-like symptoms after vaccination, 42 showed warning signs serious enough to demand urgent investigation by health authorities.
- The suspension applies only to the Butantan vaccine given to those over 15, while the Takeda vaccine continues normally for children and adolescents aged 10 to 14.
- Health officials stress the pause is temporary and precautionary — investigators must determine whether the vaccine, the disease itself, or another factor entirely caused the deaths.
- Doses already distributed to states will stay in cold storage rather than be recalled, held in reserve pending the outcome of a specialist committee review with no set timeline.
Brazil's Health Ministry suspended its dengue vaccination campaign using the Butantan Institute's vaccine on June 9th, after routine surveillance detected two deaths and three cases of severe illness among people who had received the shot. The decision was precautionary: authorities needed to determine whether the vaccine was responsible before the program could continue.
The Butantan-DV vaccine had passed all regulatory and clinical hurdles before its rollout. But monitoring data revealed troubling signals — among 3,703 people reporting dengue-like symptoms post-vaccination, 42 showed warning signs requiring investigation. Three escalated to intensive care, and two of those patients died. Eder Gatti, director of the National Immunization Program, described the suspension as a safeguard while investigators work to establish whether the vaccine caused these outcomes or whether they were coincidental.
The pause affects only the Butantan vaccine, administered to people over 15. The Takeda vaccine, used for children and adolescents aged 10 to 14, continues without interruption. People vaccinated more than three weeks before the announcement face no ongoing risk; those vaccinated more recently were advised to watch for fever, rashes, bleeding, or vomiting and seek care if symptoms appear. Doses already in state storage will be kept refrigerated rather than recalled.
A joint investigation between the Health Ministry and Butantan Institute is underway, with a specialist committee being assembled to review the data. No timeline exists for a final decision. Officials were careful to frame the episode not as a crisis of confidence, but as proof that Brazil's surveillance system functions as intended — catching rare adverse signals quickly enough to act before more people could be affected.
Brazil's Health Ministry halted the dengue vaccination campaign using the Butantan Institute's vaccine on Monday, June 9th, after the National Immunization Program's monitoring system detected a cluster of severe adverse reactions and two deaths among people who had received the shot. The decision came as a precautionary measure while health authorities investigate whether the vaccine itself was responsible for the deaths and complications.
The Butantan-DV vaccine had already cleared regulatory approval from Anvisa and completed all phases of clinical testing before its rollout. But routine surveillance by the Health Ministry uncovered troubling signals in the data: among 3,703 people who reported dengue-like symptoms after vaccination, 42 showed what officials call warning signs—indicators that suggested something had gone wrong. Three of those cases escalated to severe illness requiring intensive care, and two of those patients died.
Eder Gatti, director of the National Immunization Program's department, explained the reasoning behind the suspension. The ministry had identified more than half a million people vaccinated by May 30th. Of those, the vast majority experienced no problems. But the presence of three grave cases and two fatalities, even in a population that large, was enough to trigger a halt. Gatti emphasized that the suspension was temporary and precautionary—the goal was to determine whether the vaccine was actually causing these outcomes or whether the deaths and severe illness were coincidental. "We took this decision to suspend temporarily," he said, describing the move as a safeguard until the connection could be fully clarified.
The suspension applies only to the Butantan vaccine, which was being administered to people over 15 years old. Brazil's other dengue vaccine, made by the Takeda pharmaceutical company, continues to be distributed normally for children and adolescents aged 10 to 14. That distinction matters: the country's immunization system is not halting dengue protection across the board, only pausing one vaccine while questions about its safety are resolved.
People who received the Butantan shot more than three weeks before the suspension announcement face no ongoing risk, according to health officials. Those vaccinated in the three weeks prior should watch for fever, body aches, rashes, bleeding, or vomiting—symptoms that would warrant a visit to a health clinic. The vaccine doses already distributed to states will remain in cold storage rather than being recalled, preserving them for potential future use if the investigation clears the vaccine.
The Health Ministry and Butantan Institute have launched a joint investigation, with a committee of specialists being assembled to review the data. Gatti acknowledged that no timeline exists yet for a final decision on whether vaccinations can resume. The investigation will need to determine whether the deaths and severe cases were caused by the vaccine, by dengue infection itself, or by some other factor entirely.
Despite the suspension, ministry officials framed the episode as evidence that Brazil's vaccine surveillance system works. The fact that the monitoring program caught these rare and unexpected events quickly enough to halt the campaign before more people could be affected demonstrates the system's value. Gatti characterized it as proof that the National Immunization Program fulfills its core mission: protecting the population by ensuring the safety of vaccines offered to Brazilians.
Notable Quotes
We took this decision to suspend temporarily, until the relationship with the vaccine is totally clarified— Eder Gatti, director of the National Immunization Program
The suspension demonstrates the efficiency of our surveillance system, which identified these rare and unexpected events and allowed rapid protective action— Health Ministry statement via Eder Gatti
The Hearth Conversation Another angle on the story
Why suspend the entire vaccine if only 42 out of 501,000 people showed warning signs? Isn't that an extremely small percentage?
It is small, yes—but those 42 cases included three people who became severely ill enough to need intensive care, and two of them died. When you're talking about deaths, the percentage matters less than the signal itself. The question isn't whether it's statistically rare; it's whether the vaccine caused it.
But couldn't those people have just gotten dengue naturally after vaccination? How do you know the vaccine is responsible?
Exactly. That's what the investigation is for. The surveillance system flagged the pattern—people getting sick shortly after vaccination—but flagging a pattern isn't the same as proving causation. They need to look at the cases individually, check for other risk factors, compare to what would normally happen in an unvaccinated population.
So they're essentially saying "we don't know if this is the vaccine's fault, so we're stopping until we figure it out."
That's the precautionary principle in action. Half a million people had already been vaccinated. If there's even a possibility the vaccine is causing deaths, you pause and investigate rather than continuing to vaccinate while you're uncertain.
What about the people who still need dengue protection? Are they just left unprotected?
Not entirely. The Takeda vaccine is still available for younger people. And for adults, the suspension is temporary—if the investigation clears the Butantan vaccine, it goes back into use. If it doesn't, then Brazil needs to figure out what went wrong and fix it.
How long does an investigation like this usually take?
The official answer is: they don't know yet. Gatti said it's too early to say when they'll have a definitive decision. It depends on how complex the cases are, how much data needs to be reviewed, and whether the pattern becomes clearer or murkier as they dig deeper.